FirstWord

Investments in pharmaceutical compounds developed in China could be banned under a new rule proposed Thursday.

The oral macrocyclic peptide will be developed for inflammatory bowel diseases.

The biotech is developing NLRP3 inhibitors for cardiovascular and neuroinflammatory diseases.

The partners plan to explore the virtual models across multiple disease areas, starting with lung health, in a bid to rethink drug trials.

Early data published in NEJM points to improved saliva production in six head and neck cancer patients with chronic xerostomia.

Faster and higher expansion of tumor-targeting CD8 T cells associated with longer overall survival in previously treated mismatch repair proficient (pMMR) metastatic colorectal cancerEO4010 was well t...

EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients...

Data updates from the ongoing Phase 1 dose-escalation study demonstrated promising therapeutic index in patients with mCRPCNo dose-limiting toxicities observed; xerostomia has been predominantly Grade...

Median DOR of 44.3 months supports durability of response4-year overall survival rate of 35.3% and median OS of 28.2 months suggest meaningful long-term survivalLong-term survival of 42+ - 60+ months ...

With a median follow-up of over 14 months, ADVC001, a novel Lead-212 PSMA therapy, continues to show favorable tolerability with no new safety signals in metastatic androgen pathway modulation-resista...